MDXG - MiMedx announces commercial launch of EPIFIX product in Japan with distribution deal
- MiMedx Group ( NASDAQ: MDXG ) on Wednesday said it had entered into an exclusive distribution agreement with Japan's Gunze Medical for sales of its EPIFIX product.
- MDXG stock gained 7.3% to $3.22 after hours.
- MDXG's EPIFIX is a placental tissue allograft that can be used to provide a protective barrier over wounds.
- MDXG previously received regulatory approval for EPIFIX from Japan's health ministry in June 2021 and reimbursement approval in Sept. 2022.
- Gunze Medical is a unit of Japan's Gunze, which is a developer and manufacturer of medical devices, plastic films, engineering plastics and various other segments.
- Gunze Medical has a team of over 90 sales representatives and support staff nationwide, as well as existing clinician relationships.
For further details see:
MiMedx announces commercial launch of EPIFIX product in Japan with distribution deal